Ga-FAPI-46
Phase 2Small molecule
Ga-FAPI-46 is one of 76 small molecule programs targeting Imaging. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
65 competitors in Breast Carcinoma
#DrugCompanyPhaseTrials
1Ibrance
PfizerApproved
Afinitor
NovartisApproved
Mektovi
PfizerApproved
Piqray
NovartisApproved
Tykerb
NovartisApproved
Gemzar
Johnson & JohnsonApproved
Tagrisso
AstraZenecaApproved
Kisqali
NovartisApproved
Aromasin
PfizerApproved
Verzenio
Eli LillyApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ga-FAPI-46. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversität Münster